Imagene Health

What Imagene Health does

Imagene Health S.A. de C.V. is a Mexican precision-oncology company that provides next-generation sequencing (NGS) genomic testing for cancer alongside an integrated AI-powered oncology data platform. Founded in 2021 and headquartered in San Pedro Garza García, Nuevo León, with an additional office in Ciudad de México, the company operates a COFEPRIS-authorized laboratory under sanitary permit 223301201A2839 and holds ISO 9001:2015 certification. Its diagnostic portfolio comprises seven NGS panels led by the flagship ImageneSeq+ (500+ genes, DNA+RNA, TMB/MSI/HRD, 15-day turnaround) and six specialized panels (ImageneSeq, ColonSeq, MammaSeq, NeumoSeq, UroSeq, ImageneScreen), all using simultaneous DNA and RNA analysis and supported by international orthogonal analytical validation at 99.8% claimed precision.

The company's product architecture is organized around ImagenePlatform, a centralized cloud oncology operating system with four modules: ImageneRecords (digital EMR), ImageneLabs (NGS sequencing services), ImageneGPT (a conversational AI assistant with 2.3-second response time), and ImageneInsights (predictive analytics for drug demand forecasting and clinical trial matching). Imagene Health distributes through field sales to hospitals and oncology centers, physician-directed ordering, a direct-to-consumer self-registration portal, government health-intelligence dashboards, and pharma clinical-trial recruitment channels. Pricing is quote-based and positioned at a cost-advantaged '$' tier relative to international competitors Foundation Medicine, Guardant Health, and Tempus, which are positioned at '$$$$'. Customer segments include hospitals and oncology centers (31 active partners), pharmaceutical companies, Mexican government health authorities, oncologists, and patients, with reported outcomes including a 75% reduction in processing time at one hospital partner and $47M in claimed savings for a public health institution.

Name

Imagene Health

Legal name

Imagene Health S.A. de C.V.

Website

https://imagenehealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Imagene Health is a Mexican precision-oncology company providing COFEPRIS-authorized NGS genomic cancer testing and an AI-powered oncology data platform, serving hospitals, oncologists, patients, government health agencies, and pharmaceutical companies across Mexico.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Genomic cancer testing
• Precision oncology diagnostics
• NGS tumor profiling
• Oncology data platform
• Molecular diagnostics services

Headquarters

HQ city

Garza García

HQ country

Mexico

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Genetic Testing Services: NGS-based genomic testing panels sold to hospitals, oncologists, and patients. Multiple specialized panels (ImageneSeq+, ImageneSeq, ColonSeq, MammaSeq, NeumoSeq, UroSeq, ImageneScreen) with 15-day turnaround. Revenue per test, quote-based pricing.
2. ImagenePlatform SaaS Subscription: Cloud-based oncology operating system with EMR, sample tracking, and AI analytics. Multi-role access for hospitals, government, pharma, physicians, and patients. HIPAA and ISO 27001 compliant platform access.
3. Clinical Trial Matching Services: AI-powered patient cohort identification for pharmaceutical companies to accelerate clinical trial recruitment. Pharma pays for access to real-world evidence and market intelligence dashboards.
4. Government Health Intelligence: Real-time national health intelligence dashboards for Mexican government, providing biomarker prevalence, drug demand forecasting (95% accuracy), and genomic data for policy decisions.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Imagene Health operates an NGS-based genomic testing laboratory and an integrated oncology operating system (ImagenePlatform) for the Mexican market. The company sells comprehensive genomic profiling panels covering 500+ genes with simultaneous DNA and RNA sequencing, alongside a cloud platform that unifies EMR, sample tracking, AI analytics, and clinical trial matching for hospitals, oncologists, pharmaceutical companies, and government health agencies.

Product overview

Imagene Health operates as a platform-plus-modules architecture centered on ImagenePlatform, an operating system unifying laboratories, hospitals, government health agencies, and pharmaceutical companies for precision oncology in Mexico. The platform integrates four core modules: ImageneRecords (digital EMR), ImageneLabs (NGS sequencing services), ImageneGPT (conversational AI), and ImageneInsights (predictive analytics). The diagnostic product portfolio comprises seven NGS testing panels led by ImageneSeq+ (500+ genes, flagship tumor-agnostic panel), ImageneSeq (160 genes, DNA+RNA with fusion detection), and five organ-specific panels: ColonSeq (colorectal), MammaSeq (breast/ovarian), NeumoSeq (lung), UroSeq (urological), and ImageneScreen (hereditary whole exome). All tests leverage 15-day turnaround with COFEPRIS authorization and ISO 9001:2015 certification.

Differentiator

Problem solved

Functional benefit

Brands

• ImageneSeq+: Flagship comprehensive tumor-agnostic genomic profiling panel covering 500+ genes with DNA+RNA analysis, TMB/MSI/HRD biomarkers, and liquid biopsy compatibility.
• ImageneSeq
• ColonSeq
• MammaSeq
• NeumoSeq
• UroSeq
• ImageneScreen
• ImagenePlatform
• ImageneLabs
• ImageneGPT
• ImageneInsights
• ImageneRecords

Products and services

• ImagenePlatform Centralized cloud-based oncology operating system unifying laboratories, hospitals, government, and pharmaceutical companies. Includes EMR, sample tracking, automated workflows, AI-powered analytics, and multi-stakeholder dashboards.
• ImageneSeq+ Flagship tumor-agnostic comprehensive genomic profiling panel analyzing 500+ genes using simultaneous DNA and RNA sequencing, including TMB, MSI, and HRD biomarkers. Compatible with FFPE and liquid biopsy samples with 15-day turnaround.
• ImageneSeq Comprehensive 160-gene NGS panel with simultaneous DNA and RNA analysis detecting SNVs, indels, CNVs, and gene fusions (ALK, ROS1, NTRK, RET, FGFR2, NRG1). Covers more than 95% of actionable variants per NCCN/ESMO guidelines.
• ColonSeq Specialized 92-gene NGS panel for colorectal cancer with extended RAS/BRAF analysis, MSI evaluation, and HER2/NTRK biomarkers. Identifies actionable mutations in 89% of colorectal cancer patients.
• MammaSeq Dual germinal and somatic analysis panel for breast and ovarian cancer including complete BRCA1/2 analysis, HRD scoring for PARP inhibitor guidance, and hereditary syndrome identification. Includes cascade family testing.
• NeumoSeq Lung cancer NGS panel covering EGFR, ALK, ROS1, BRAF, and 10+ actionable genes with integrated DNA+RNA analysis for fusion detection. Identifies actionable mutations in 60-80% of lung cancer patients.
• UroSeq Specialized 92-gene NGS panel for prostate mCRPC and urological cancers with HRD evaluation for PARP inhibitor therapy and AR pathway analysis for hormonal therapy resistance. Identifies treatable mutations in 89% of mCRPC patients.
• ImageneScreen Whole exome panel for hereditary cancer conditions analyzing 94 genes associated with more than 25 hereditary cancer syndromes including BRCA, Lynch syndrome, and Li-Fraumeni. Supports family cascade testing.

Quantifiable outcome

• 67% of patients have treatable mutations detected by NGS (general); 87% with ImageneSeq+ flagship panel
• +8 more outcomes

Named customers6 records

Segments1 record

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered core.

• Hospital SwisscoreStrategic or Co-development PartnerStrategic hospital partnership for genomic testing services. Hospital refers patients for NGS testing and accesses ImagenePlatform for integrated EMR and sample tracking. Represents one of 31 active hospital partnerships in Mexico.
• SaCencoreStrategic or Co-development PartnerStrategic partnership for cancer center operations and genomic testing referral network across Mexico.
• Auna Doctors HospitalcoreStrategic or Co-development PartnerHospital partnership providing oncology genomic testing services and platform integration for patient management and sample tracking.
• I CAN Oncology CentercoreStrategic or Co-development PartnerOncology center partnership for genomic profiling referrals and integrated clinical decision support using ImagenePlatform.
• Centro de Oncología Avanzado del NorestecoreStrategic or Co-development PartnerAdvanced oncology center in northeastern Mexico providing genomic testing referrals and accessing AI-powered oncology platform for treatment optimization.
• Clínica Opción OncologíacoreStrategic or Co-development PartnerOncology clinic partnership for precision medicine implementation and genomic testing services for cancer patients.
• Centro de Excelencia OncológicacoreStrategic or Co-development PartnerCenter of excellence partnership for advanced oncology care and comprehensive genomic profiling integration.
• Morgan Centro de Alta EspecialidadcoreStrategic or Co-development PartnerHigh-specialty center partnership providing genomic testing referrals and integrated oncology platform access for patient care.

Scale indicators22 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Genomma Lab: Latin American pharmaceutical and diagnostics player. While not a direct NGS competitor, represents a regional incumbent with established Mexican healthcare distribution that Imagene Health may encounter as a partner or competitor in scaling oncology services across LatAm.

Direct peers

• Personalis: Cancer genomics company offering comprehensive NGS tumor profiling (NeXT Personal) and biopharma CDx services. Directly comparable in NGS panel scope and pharma services orientation.
• NeoGenomics: Cancer-focused molecular laboratory offering NGS panels, liquid biopsy, and pharma services. Competes in oncology genetic testing with similar hospital and oncology center customer base.
• Caris Life Sciences: Direct peer in comprehensive molecular profiling (MI Profile) with DNA+RNA sequencing, TMB/MSI/HRD biomarkers, and biopharma partnerships. Competes in the same comprehensive genomic profiling category as ImageneSeq+.
• Tempus Labs: Closest peer in AI-powered oncology data platform with NGS testing, EMR integration, clinical trial matching, and pharma R&D services. Imagene's ImagenePlatform+ImageneGPT+ImageneInsights architecture closely mirrors Tempus's platform-plus-modules model.
• Foundation Medicine (Roche): Direct NGS-based comprehensive genomic profiling competitor with flagship FoundationOne CDx and FoundationOne Liquid CDx products. Named as a competitor in Imagene's own comparison table; serves oncologists globally with the same tumor-agnostic profiling model.
• Veracyte: Molecular diagnostics company with genomic testing across oncology indications, including similar tumor-specific panels. Offers comparable hospital-based sales motion and integrated genomic reporting.
• Guardant Health: Direct competitor in oncology genomics with liquid biopsy NGS panels (Guardant360) and a biopharma services business. Imagene's ImageneSeq+ competes head-to-head with Guardant's tumor profiling offering in the same customer base of oncologists and pharma companies.

Broad incumbents

• Myriad Genetics: Established molecular diagnostics company with hereditary cancer testing (BRACAnalysis, MyRisk) and oncology profiling. Directly comparable in hereditary cancer screening (vs ImageneScreen) and BRCA1/2 analysis (vs MammaSeq).
• Natera: Larger molecular diagnostics company with Signatera oncology MRD test plus broader women's health and organ health offerings. Adjacent competitor in oncology genomics with deeper commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/imagene-health

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imagene Health